Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | See Remarks | October 31, 2024 | November 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKET PHARMACEUTICALS, INC.
Report date October 31, 2024 · Filed November 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,140 |
Reported balance
After 2024-10-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-10-31 · Sale · Disposed 3,080 · Balance 69,140 F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2024 Filed Nov 4, 2024 21:06 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 3,080 | $16.63 | $51,205.00 |
DisclosureSEC source: 0001140361-24-045101 · form4.xml · nonDerivative · entry 1 White Mark Andrew · CIK 0001973240 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,140 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 3,026 | $20.40 | $61,715.27 |
DisclosureSEC source: 0001140361-24-032761 · form4.xml · nonDerivative · entry 1 White Mark Andrew · CIK 0001973240 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,220 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. RSUs vest one-third (1/3) upon the first anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:39 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 12,532 | $24.64 | $308,763.42 |
DisclosureSEC source: 0001140361-24-019167 · form4.xml · nonDerivative · entry 1 White Mark Andrew · CIK 0001973240 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,226 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. RSUs vest one-third (1/3) upon the first anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 32,727 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001140361-24-008887 · form4.xml · derivative · entry 2 White Mark Andrew · CIK 0001973240 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,727 Underlying: Common Stock · 32,727 shares Expires 2034-02-16 F2 · derivative.exercise_date: This option represents a right to purchase a total of 32,727 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 11,096 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008887 · form4.xml · nonDerivative · entry 1 White Mark Andrew · CIK 0001973240 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,758 F1 · security: Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · shares: Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| April 04, 2023 Filed Apr 12, 2023 23:00 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 57,739 | $0.00 Strike: $17.41 | $0.00 |
DisclosureSEC source: 0001140361-23-018047 · form4.xml · derivative · entry 2 White Mark Andrew · CIK 0001973240 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,739 Underlying: Common Stock · 57,739 shares Expires 2033-04-04 F2 · derivative.exercise_date: This option represents a right to purchase a total of 57,739 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| April 04, 2023 Filed Apr 12, 2023 23:00 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock, par value $0.01 | 76,662 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-018047 · form4.xml · nonDerivative · entry 1 White Mark Andrew · CIK 0001973240 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,662 F1 · shares: Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · balance_after: Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.